Scotiabank raised the firm’s price target on Vera Therapeutics (VERA) to $65 from $55 and keeps an Outperform rating on the shares.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VERA:
- Buy Rating for Vera Therapeutics: Promising Potential of Atacicept in IgA Nephropathy Treatment
- Arthur He CFA Upgrades Vera Therapeutics on Promising Phase 3 Results for Atacicept in IgAN Treatment
- H.C. Wainwright ups Vera Therapeutics target on ‘home run’ data
- Vera Therapeutics Announces Positive Phase 3 Trial Results
- Vera Therapeutics: Primary endpoint was met in ORIGIN Phase 3 trial of atacicept
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue